Year: 2022
BerGenBio Reports Second Quarter and Half Year 2022 Financial Results and Provides Business Update
August 23, 2022
- Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients - - Initiation of Phase…
Read MoreBERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
June 6, 2022
Bergen, Norway, 6 June 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
May 24, 2022
Bergen, Norway, 24 May 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read MoreBERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
May 4, 2022
BerGenBio to focus on two key opportunities for its lead compound bemcentinibStrategic focus anchored in…
Read MoreBERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS – PRIMARY EFFICACY ENDPOINT MET
April 26, 2022
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary…
Read MoreBERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022
April 25, 2022
Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
